7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging)

CBCN Certified Breast Care Nurse Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CBCN Exam

CBCN Exam Facts, 2026 Blueprint & Study Plan

2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)

1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes

3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)

2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations

4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)

3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation

5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)

4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance

6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)

5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques

7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)

6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification

8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)

7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET

9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)

8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery

10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)

9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens

11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)

10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs

12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)

11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations

13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)

12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy

14 Chapter 13: Oncologic Emergencies (Nursing Practice)

13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism

15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)

14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use

16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)

15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health

7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging)

Key Takeaways Explain This Topic AI

The AJCC 8th edition staging framework establishes Clinical Prognostic Staging and Pathological Prognostic Staging, incorporating anatomic TNM plus histologic grade, ER, PR, HER2, and multigene assay results.

Primary tumor classification (T) ranges from microinvasion (T1mi 0.1 cm or less) to locally advanced tumors (T4) extending directly into the chest wall, skin, or presenting as inflammatory breast cancer.

Pathologic regional lymph node staging (pN) separates isolated tumor cells (pN0[i+] 0.2 mm or less) and micrometastases (pN1mi greater than 0.2 mm to 2.0 mm or less) from macrometastases (pN1a greater than 2.0 mm).

Inflammatory breast cancer is classified as T4d based on rapid clinical presentation with diffuse erythema and edema (peau d'orange) involving at least one-third of the breast, even if skin punch biopsy lacks dermal lymphatic tumor emboli.

Biologic prognostic staging dynamically upstages aggressive, high-grade triple-negative tumors and downstages low-grade, hormone receptor-positive tumors relative to traditional anatomic stage groupings.

Last updated: September 2026

Cancer staging establishes a standardized language to quantify tumor burden, direct local and systemic therapy, estimate prognosis, and evaluate oncology outcomes. The American Joint Committee on Cancer (AJCC) Staging Manual, 8th Edition, represents a major paradigm shift in breast oncology by transitioning from a purely anatomic classification to an integrated prognostic staging system that incorporates tumor biology.

The Staging Paradigm: Anatomic vs. Prognostic Staging

For decades, breast cancer staging depended exclusively on anatomic metrics: the size of the primary tumor (T), the extent of regional lymph node involvement (N), and the presence or absence of distant metastases (M). However, patients with identical anatomic stages frequently experience markedly divergent clinical courses driven by underlying biological differences. For example, a patient with an anatomic Stage IIA tumor (2.5 cm, node-negative) that is Grade 1, ER-positive, PR-positive, and HER2-negative has a 5-year survival exceeding 98%. Conversely, a patient with the exact same anatomic tumor dimensions (2.5 cm, node-negative) that is Grade 3, ER-negative, PR-negative, and HER2-negative (triple-negative) faces a substantially higher risk of early visceral recurrence and mortality.

To resolve this discordance, the AJCC 8th Edition introduced two comprehensive staging structures:

Clinical Prognostic Stage : Determined prior to definitive surgery based on clinical history, physical examination, pre-treatment imaging (mammography, ultrasound, MRI, systemic imaging), core needle biopsy histologic grade, and biomarker status (ER, PR, HER2). It guides the selection of pre-operative (neoadjuvant) systemic therapy versus primary surgical resection.

Pathological Prognostic Stage : Determined after definitive surgical resection of the primary breast tumor and regional lymph nodes in patients who have not received neoadjuvant therapy. It integrates surgical pathology metrics (pathologic T, pathologic N, histologic grade, ER, PR, HER2) and, where indicated, multigene genomic assay recurrence scores (such as Oncotype DX). It governs adjuvant systemic chemotherapy, endocrine therapy, targeted agents, and post-mastectomy or regional nodal radiation therapy.

Note: For patients who receive neoadjuvant systemic therapy, post-neoadjuvant pathologic staging is documented using the prefix "yp" (e.g., ypT0 ypN0 cM0 for a complete pathologic response). However, prognostic stage tables apply strictly to treatment-naive clinical staging or primary surgical pathological staging.

Primary Tumor (T Category)

The primary tumor category reflects the maximum dimension of the single largest contiguous focus of invasive carcinoma. In multifocal or multicentric disease, the T stage is assigned using only the largest individual focus (with a modifier designating multiple foci, such as T1c[m]), not the cumulative sum of all foci.

TX : Primary tumor cannot be assessed (e.g., resected elsewhere without pathologic records).

T0 : No evidence of primary tumor in the breast (e.g., patient presenting with biopsy-proven metastatic adenocarcinoma in an axillary node without an identifiable breast lesion).

Tis (DCIS) : Ductal carcinoma in situ.

Tis (Paget) : Paget disease of the nipple with no associated underlying invasive carcinoma or DCIS in the breast parenchyma. (Note: Lobular carcinoma in situ [LCIS] is classified as a benign neoplastic risk condition and has been completely removed from the AJCC staging system).

T1 : Tumor 2.0 cm or less in greatest dimension:

T1mi : Microinvasion 0.1 cm (1 mm) or less in greatest dimension.

T1a : Tumor greater than 0.1 cm but not more than 0.5 cm in greatest dimension.

T1b : Tumor greater than 0.5 cm but not more than 1.0 cm in greatest dimension.

T1c : Tumor greater than 1.0 cm but not more than 2.0 cm in greatest dimension.

T2 : Tumor greater than 2.0 cm but not more than 5.0 cm in greatest dimension.

T3 : Tumor greater than 5.0 cm in greatest dimension.

T4 : Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic satellite skin nodules):

T4a : Extension to the chest wall, defined as invasion of the ribs, intercostal muscles, or serratus anterior muscle. Note: Invasion of or adherence to the pectoralis major or minor muscle alone does not qualify as T4a.

T4b : Ulceration, macroscopic ipsilateral satellite skin nodules, or skin edema (including peau d'orange) that does not meet the diagnostic criteria for inflammatory breast cancer.

T4c : Both T4a and T4b criteria present concurrently.

T4d : Inflammatory breast cancer. This is a clinical diagnosis characterized by rapid onset of diffuse erythema, warmth, and edema (peau d'orange) involving at least one-third (33%) of the breast skin. Dermal lymphatic tumor emboli may be identified on skin punch biopsy, but histologic presence of emboli is neither required nor sufficient on its own to assign T4d without the classic clinical presentation.

Regional Lymph Nodes (N Category)

Regional nodal staging is divided into clinical (cN) and pathological (pN) classifications. Pathologic staging requires histological examination of resected sentinel lymph nodes or completion axillary lymph node dissection (ALND) specimens.

Pathologic Nodal Staging (pN)

pN0 : No regional lymph node metastasis histologically, or only isolated tumor cells.

pN0(i+) : Isolated tumor cells (ITCs) present as single cells or small clusters of cells measuring 0.2 mm or less, or containing fewer than 200 tumor cells in a single cross section. Biologically and clinically, ITCs are classified as node-negative (Stage 0/I).

pN1mi : Micrometastases present, defined as metastatic tumor deposits larger than 0.2 mm but not more than 2.0 mm, or clusters of more than 200 cells.

pN1 : Metastasis in 1 to 3 axillary lymph nodes (macrometastases exceeding 2.0 mm), and/or in internal mammary nodes with microscopic disease detected by sentinel lymph node biopsy:

pN1a : Metastases in 1 to 3 axillary lymph nodes (at least one deposit greater than 2.0 mm).

pN1b : Metastases in internal mammary sentinel nodes (excluding ITCs) detected by sentinel lymph node biopsy without axillary nodal macrometastases.

pN1c : Both pN1a and pN1b criteria met concurrently.

pN2 : Metastasis in 4 to 9 axillary lymph nodes, or clinically apparent internal mammary lymph nodes in the absence of axillary nodal metastasis:

pN2a : Metastases in 4 to 9 axillary lymph nodes (at least one deposit greater than 2.0 mm).

pN2b : Metastases in clinically apparent internal mammary lymph nodes detected by imaging or clinical exam, in the absence of axillary nodal macrometastases.

pN3 : Advanced regional nodal metastasis:

pN3a : Metastases in 10 or more axillary lymph nodes; or metastases in infraclavicular (Level III axillary) lymph nodes.

pN3b : Metastases in clinically apparent ipsilateral internal mammary lymph nodes in the presence of 1 or more positive axillary lymph nodes; or metastases in greater than 3 axillary nodes with microscopic internal mammary sentinel node disease.

pN3c : Metastases in ipsilateral supraclavicular lymph nodes, regardless of the status of axillary or internal mammary nodes.

Distant Metastasis (M Category)

M0 : No clinical or radiographic evidence of distant metastases.

cM0(i+) : No clinical or radiographic evidence of distant metastases, but microscopic tumor cells are detected by cytology or molecular methods in circulating blood, bone marrow, or other non-regional tissues, with no deposit exceeding 0.2 mm in a non-regional lymph node.

M1 : Distant metastasis documented by clinical, radiographic, or histologic means. Common metastatic sites include bone (involved in up to about 70% of patients with metastatic disease), lungs, liver, and brain.

Stage Groupings and Prognostic Stage Migration

Anatomic stage groupings integrate T, N, and M metrics into Stages 0, I, II, III, and IV:

Stage 0 : Tis N0 M0
Stage IA : T1 N0 M0
Stage IB : T0/T1 N1mi M0
Stage IIA : T0-1 N1 M0, or T2 N0 M0
Stage IIB : T2 N1 M0, or T3 N0 M0
Stage IIIA : T0-2 N2 M0, or T3 N1-2 M0
Stage IIIB : T4 N0-2 M0
Stage IIIC : Any T N3 M0
Stage IV : Any T Any N M1
Clinical and Pathological Prognostic Stage Migration

When biologic factors (Histologic Grade, ER, PR, HER2) and genomic recurrence scores are integrated, patients frequently migrate to a different prognostic stage compared to their anatomic stage:

Prognostic Downstaging (Favorable Biology) : A patient with an anatomic Stage IIA tumor (T2 N0 M0, 2.8 cm) that is Histologic Grade 1, ER-positive, PR-positive, and HER2-negative is assigned Pathological Prognostic Stage IA . The favorable biology indicates an excellent long-term survival trajectory.

Prognostic Upstaging (Unfavorable Biology) : A patient with the exact same anatomic Stage IIA tumor (T2 N0 M0, 2.8 cm) that is Histologic Grade 3, ER-negative, PR-negative, and HER2-negative (Triple-Negative) is assigned Clinical Prognostic Stage IIB before surgery. The aggressive biologic profile reflects higher proliferation and early recurrence risk.

Genomic Downstaging : In the AJCC 8th edition, patients with hormone receptor-positive, HER2-negative, node-negative breast cancer (T1-T2 N0 M0) who have an Oncotype DX Recurrence Score of less than 11 are placed in Pathological Prognostic Stage IA , regardless of histologic grade.

Staging Component Anatomic Stage Input Biologic Prognostic Input Clinical Application

Tumor Size (T) Maximum diameter of single largest invasive focus Integrated with grade and biomarkers Directs breast conservation vs. mastectomy; neoadjuvant eligibility

Nodal Status (N) Number and anatomic level of positive lymph nodes Micrometastases vs. macrometastases Governs axillary dissection vs. radiation fields (regional nodal irradiation)

Histologic Grade Not included in anatomic staging Nottingham Grade (tubule formation, nuclear pleomorphism, mitotic count: G1, G2, G3) Essential modifier; G3 drives prognostic upstaging

ER / PR Status Not included in anatomic staging Immunoreactivity percentage (positive vs. negative) Predicts endocrine response; ER+ confers prognostic downstaging

HER2 Status Not included in anatomic staging IHC/FISH amplification status Predicts targeted antibody benefit; impacts both clinical and pathologic stage

Genomic Assay Not included in anatomic staging Oncotype DX Recurrence Score (<11 assigns Stage IA) Refines risk stratification in ER+/HER2- pN0 disease

Nursing Considerations in Cancer Staging

Breast care nurses play a critical role in educating patients and mitigating anxiety during staging evaluations:

De-escalating Staging Anxiety : Patients often look up their tumor size and nodal findings online and assume an anatomic stage without realizing that favorable biomarker profiles (ER+/PR+/HER2-) frequently downstage their clinical or pathologic prognosis to Stage I.

Explaining Biopsy vs. Surgical Stage : Clarify that the initial stage provided at biopsy is a provisional Clinical Prognostic Stage , which may be refined after definitive surgical pathology into the Pathological Prognostic Stage .

Communicating Inflammatory Carcinoma Risks : Recognize that T4d inflammatory breast cancer is an oncologic emergency requiring prompt multi-agent neoadjuvant chemotherapy rather than upfront surgery, and educate patients on monitoring skin erythema and edema.